Genetics and biological therapies for Alport syndrome

Bibliography

• Guthrie LG. “Idiopathic”, or congenital, hereditary and familial hematuria. Lancet 1902;1:1243-6
   Google Scholar
• Eason J, Smith GLM. Hereditary and familial nephritis. Lancet 1924;2:639
   Google Scholar
• Hurst AF. Hereditary familial congenital haemorrhagic nephritis occurring in sixteen individuals in three generations. Guy’s Hosp Rep 1923;3:368-70
   Google Scholar
• Kendall G, Hertz AF. Hereditary familial congenital haemorrhagic nephritis. Guy’s Hosp Rep 1912;66:137-41
   Google Scholar
• Alport AC. Hereditary familial congenital haemorrhagic nephritis. Br Med J 1927;1:504-6
   PubMedGoogle Scholar
• Churg J, Sherman RL. Pathologic characteristics of hereditary nephritis. Arch Pathol 1973;95:374-9
   PubMedGoogle Scholar
• Hinglais N, Grunfeld J-P, Bois LE. Characteristic ultrastructural lesion of the glomerular basement membrane in progressive hereditary nephritis (Alport’s syndrome). Lab Invest 1972;27:473-87
   PubMed Web of Science ®Google Scholar
• Spear GS, Slusser RJ. Alport’s syndrome: emphasizing electron microscopic studies of the glomerulus. Am J Pathol 1972;69:213-22
   PubMed Web of Science ®Google Scholar
• Atkin CL, Hasstedt SJ, Menlove L, et al. Mapping of Alport syndrome to the long arm of the X chromosome. Am J Hum Genet 1988;42:249-55
   PubMed Web of Science ®Google Scholar
• Kashtan C, Fish AJ, Kleppel M, et al. Nephritogenic antigen determinants in epidermal and renal basement membranes of kindreds with Alport-type familial nephritis. J Clin Invest 1986;78:1035-44
   PubMed Web of Science ®Google Scholar
• Barker DF, Hostikka SL, Zhou J, et al. Identification of mutations in the COL4A5 collagen gene in Alport syndrome. Science 1990;248:1224-7
   PubMed Web of Science ®Google Scholar
• Hostikka SL, Eddy RL, Byers MG, et al. Identification of a distinct type IV collagen a chain with restricted kidney distribution and assignment of its gene to the locus of X chromosome-linked Alport syndrome. Proc Natl Acad Sci USA 1990;87:1606-10
   PubMed Web of Science ®Google Scholar
• Boye E, Mollet G, Forestier L, et al. Determination of the genomic structure of the COL4A4 gene and of novel mutations causing autosomal recessive Alport syndrome. Am J Hum Genet 1998;63:1329-40
   PubMed Web of Science ®Google Scholar
• Heidet L, Arrondel C, Forestier L, et al. Structure of the human type IV collagen gene COL4A3 and mutations in autosomal Alport syndrome. J Am Soc Nephrol 2001;12:97-106
   PubMed Web of Science ®Google Scholar
• Mochizuki T, Lemmink HH, Mariyama M, et al. Identification of mutations in the alpha 3(IV) and alpha 4(IV) collagen genes in autosomal recessive Alport syndrome. Nat Genet 1994;8:77-82
   PubMed Web of Science ®Google Scholar
• Butkowski RJ, Langeveld JP, Weislander J, et al. Localization of the Goodpasture epitope to a novel chain of basement membrane collagen. J Biol Chem 1987;262:7874-7
   PubMed Web of Science ®Google Scholar
• Gunwar S, Ballester F, Noelken M, et al. Glomerular basement membrane. Identification of a novel disulfide-cross-linked network of alpha3, alpha4, and alpha5 chains of type IV collagen and its implications for the pathogenesis of Alport syndrome. J Biol Chem 1998;273:8767-75
   PubMed Web of Science ®Google Scholar
• Khoshnoodi J, Sigmundsson K, Cartailler JP, et al. Mechanism of chain selection in the assembly of collagen IV: a prominent role for the alpha2 chain. J Biol Chem 2006;281:6058-69
   PubMed Web of Science ®Google Scholar
• Saus J, Wieslander J, Langeveld JP, et al. Identification of the Goodpasture antigen as the alpha 3(IV) chain of collagen IV. J Biol Chem 1988;263:13374-80
   PubMed Web of Science ®Google Scholar
• Wieslander J, Barr JF, Butkowski R, et al. Goodpasture antigen of the glomerular basement membrane: localization to noncollagenous regions of type IV collagen. Proc Natl Acad Sci USA 1984;81:3838-42
   PubMed Web of Science ®Google Scholar
• Wieslander J, Langeveld J, Butkowski R, et al. Physical and immunochemical studies of the globular domain of type IV collagen: cryptic properties of the Goodpasture antigen. J Biol Chem 1985;260:8564-70
   PubMed Web of Science ®Google Scholar
• Kalluri R, Shield CF, Todd P, et al. Isoform switching of type IV collagen is developmentally arrested in X-linked Alport syndrome leading to increased susceptibility of renal basement membranes to endoproteolysis. J Clin Invest 1997;99:2470-8
   PubMed Web of Science ®Google Scholar
• Kashtan CE, Kim Y. Distribution of the alpha 1 and alpha 2 chains of collagen IV and of collagens V and VI in Alport syndrome. Kidney Int 1992;42:115-26
   PubMed Web of Science ®Google Scholar
• Kleppel MM, Santi PA, Cameron JD, et al. Human tissue distribution of novel basement membrane collagen. Am J Pathol 1989;134:813-25
   PubMed Web of Science ®Google Scholar
• Zehnder AF, Adams JC, Santi PA, et al. Distribution of type IV collagen in the cochlea in Alport syndrome. Arch Otolaryngol Head Neck Surg 2005;131:1007-13
   PubMedGoogle Scholar
• Gyoneva L, Segal Y, Dorfman KD, et al. Mechanical response of wild-type and Alport murine lens capsules during osmotic swelling. Exp Eye Res 2013;113:87-91
   PubMed Web of Science ®Google Scholar
• Kato T, Watanabe Y, Nakayasu K, et al. The ultrastructure of the lens capsule abnormalities in Alport’s syndrome. Jpn J Ophthalmol 1998;42:401-5
   PubMed Web of Science ®Google Scholar
• Streeten BW, Robinson MR, Wallace R, et al. Lens capsule abnormalities in Alport’s syndrome. Arch Ophthalmol 1987;105:1693-7
   PubMedGoogle Scholar
• Hertz JM, Thomassen M, Storey H, et al. Clinical utility gene card for: Alport syndrome. Eur J Hum Genet 2012;20:6
   Web of Science ®Google Scholar
• Fallerini C, Dosa L, Tita R, et al. Unbiased next generation sequencing analysis confirms the existence of autosomal dominant Alport syndrome in a relevant fraction of cases. Clin Genet 2013. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Andrews KL, Mudd JL, Li C, et al. Quantitative trait loci influence renal disease progression in a mouse model of Alport syndrome. Am J Pathol 2002;160:721-30
   PubMed Web of Science ®Google Scholar
• Pochet JM, Bobrie G, Landais P, et al. Renal prognosis in Alport’s and related syndromes: influence of the mode of inheritance. Nephrol Dial Transplant 1989;4:1016-21
   PubMed Web of Science ®Google Scholar
• Bekheirnia MR, Reed B, Gregory MC, et al. Genotype-phenotype correlation in X-linked Alport syndrome. J Am Soc Nephrol 2010;21:876-83
   PubMed Web of Science ®Google Scholar
• Gross O, Netzer KO, Lambrecht R, et al. Meta-analysis of genotype-phenotype correlation in X-linked Alport syndrome: impact on clnical counseling. Nephrol Dial Transplant 2002;17:1218-27
   PubMed Web of Science ®Google Scholar
• Jais JP, Knebelmann B, Giatras I, et al. X-linked Alport syndrome: natural history in 195 families and genotype-phenotype correlations in males. J Am Soc Nephrol 2000;11:649-57
   PubMed Web of Science ®Google Scholar
• Jais JP, Knebelmann B, Giatras I, et al. X-linked Alport syndrome: natural history and genotype-phenotype correlations in girls and women belonging to to 195 families: a “European Community Alport Syndrome Concerted Action” study. J Am Soc Nephrol 2003;14:2603-10
   PubMed Web of Science ®Google Scholar
• Rheault MN, Kren SM, Hartich LA, et al. X-inactivation modifies disease severity in female carriers of murine X-linked Alport syndrome. Nephrol Dial Transplant 2010;25:764-9
   PubMed Web of Science ®Google Scholar
• Tsiakkis D, Pieri M, Koupepidou P, et al. Genotype-phenotype correlation in X-linked Alport syndrome patients carrying missense mutations in the collagenous domain of COL4A5. Clin Genet 2012;82:297-9
   PubMed Web of Science ®Google Scholar
• Kashtan CE, Gubler MC, Sisson-Ross S, et al. Chronology of renal scarring in males with Alport syndrome. Pediatr Nephrol 1998;12:269-74
   PubMed Web of Science ®Google Scholar
• Cosgrove D, Kalluri R, Miner JH, et al. Choosing a mouse model to study the molecular pathobiology of Alport glomerulonephritis. Kidney Int 2007;71:615-18
   PubMed Web of Science ®Google Scholar
• Cosgrove D, Meehan DT, Grunkemeyer JA, et al. Collagen COL4A3 knockout: a mouse model for autosomal Alport syndrome. Genes Dev 1996;10:2981-92
   PubMed Web of Science ®Google Scholar
• Miner JJ, Sanes JR. Molecular and functional defects in kidneys of mice lacking collagen alpha3(IV): implications for Alport syndrome. J Cell Biol 1996;135:1403-13
   PubMed Web of Science ®Google Scholar
• Rheault MN, Kren SM, Thielen BK, et al. Mouse model of X-linked Alport syndrome. J Am Soc Nephrol 2004;15:1466-74
   PubMed Web of Science ®Google Scholar
• Gross O, Beirowski B, Koepke ML, et al. Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome. Kidney Int 2003;63:438-46
   PubMed Web of Science ®Google Scholar
• Gross O, Koepke ML, Beirowski B, et al. Nephroprotection by antifibrotic and anti-inflammatory effects of the vasopeptidase inhibitor AVE7688. Kidney Int 2005;68:456-63
   PubMed Web of Science ®Google Scholar
• Lin X, Suh JH, Go G, et al. Feasibility of repairing glomerular basement membrane defects in Alport syndrome. J Am Soc Nephrol 2014;25:687-92
   PubMed Web of Science ®Google Scholar
• Kashtan CE, Ding J, Gregory M, et al. Clinical practice recommendations for the treatment of Alport syndrome: a statement of the Alport Syndrome Research Collaborative. Pediatr Nephrol 2013;28:5-11
   PubMed Web of Science ®Google Scholar
• Savige J, Gregory M, Gross O, et al. Expert guidelines for the management of Alport syndrome and thin basement membrane nephropathy. J Am Soc Nephrol 2013;24:364-75
   PubMed Web of Science ®Google Scholar
• Gross O, Licht C, Anders H, et al. Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy. Kidney Int 2012;81:494-501
   PubMed Web of Science ®Google Scholar
• Temme J, Peters F, Lange K, et al. Incidence of renal failure and nephroprotection by RAAS inhibition in heterozygous carriers of X-chromosomal and autosomal recessive Alport mutations. Kidney Int 2012;81:779-83
   PubMed Web of Science ®Google Scholar
• Gross O, Schulze-Lohoff E, Koepke ML, et al. Antifibrotic, nephroprotective potential of ACE inhibitor vs AT1 antagonist in a murine model of renal fibrosis. Nephrol Dial Transplant 2004;19:1716-23
   PubMed Web of Science ®Google Scholar
• Zeisberg M, Bottiglio C, Kumar N, et al. Bone morphogenic protein-7 inhibits progression of chronic renal fibrosis associated with two genetic mouse models. Am J Physiol Renal Physiol 2003;285:F1060-7
   PubMed Web of Science ®Google Scholar
• Tanaka M, Asada M, Higashi AY, et al. Loss of BMP antagonist USAG-1 ameliorates disease in a mouse model of the progressive hereditary kidney disease Alport syndrome. J Clin Invest 2010;120:768-77
   PubMed Web of Science ®Google Scholar
• Ninichuk V, Gross O, Reichel C, et al. Delayed chemokine receptor 1 blockade prolongs survival in collagen 4A3-deficient miche with Alport disease. J Am Soc Nephrol 2005;16:977-85
   PubMed Web of Science ®Google Scholar
• Gross O, Girgert R, Beirowski B, et al. Loss of collage-receptor DDR1 delays renal fibrosis in hereditary type IV collagen disease. Matrix Biol 2010;29:346-56
   PubMed Web of Science ®Google Scholar
• Ninichuk V, Gross O, Segerer S, et al. Multipotent mesenchymal stem cells reduce interstitial fibrosis but do not delay progression of chronic kidney disease in collagen4A3-deficient mice. Kidney Int 2006;70:121-9
   PubMed Web of Science ®Google Scholar
• Patel V, Noureddine L. MicroRNAs and fibrosis. Curr Opin Nephrol Hypertens 2012;21:410-16
   PubMed Web of Science ®Google Scholar
• Ho J, Ng KH, Rosen S, et al. Podocyte-specific loss of functional microRNAs leads to rapid glomerular and tubular injury. J Am Soc Nephrol 2008;19:2069-75
   PubMed Web of Science ®Google Scholar
• Zhong X, Chung AC, Chen H-Y, et al. Smad3-mediated upregulation of miR-21 promotes renal fibrosis. J Am Soc Nephrol 2011;22:1668-81
   PubMed Web of Science ®Google Scholar
• Liu G, Friggeri A, Yang Y, et al. miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. J Exp Med 2010;207:1589-97
   PubMed Web of Science ®Google Scholar
• Chau BN, Xin C, Hartner J, et al. MicroRNA 21 promotes fibrosis of the kidney by silencing metabolic pathways. Sci Transl Med 2012;4:121ra18
   PubMed Web of Science ®Google Scholar
• Chung AC, Dong Y, Yang W, et al. Smad7 suppresses renal fibrosis via altering expression of TGF- beta/Smad3-regulated microRNAs. Mol Ther 2012;21:388-98
   PubMed Web of Science ®Google Scholar
• Zhong X, Chung ACK, Chen HY, et al. miR-21 is a key therapeutic target for renal injury in a mouse model of type 2 diabetes. Diabetologia 2013;56:663-74
   PubMed Web of Science ®Google Scholar
• Gomez IG, MacKenna D, Roach AM, et al. Anti-miR21 protects Collagen 4A3 deficient mice from progression of Alport disease by decreasing oxidative stress. In: American Society of Nephrology; Atlanta, GA; 2013
   Google Scholar
• Boulanger J, Song W, Zhang J, et al. Identification of the pathologic role of miR-21 in Alport’s kidney disease. In: American Society of Nephrology Annual Meeting. Atlanta, GA; 2013
   Google Scholar
• LeBleu VS, Sugimoto H, Miller CA, et al. Lymphocytes are dispensable for glomerulonephritis but required for renal interstitial fibrosis in matrix defect-induced Alport renal disease. Lab Invest 2008;88:284-92
   PubMed Web of Science ®Google Scholar
• Jedlicka JA, Soleiman A, Draganovici D, et al. Interstitial inflammation in Alport syndrome. Hum Pathol 2010;41:582-93
   PubMed Web of Science ®Google Scholar
• Ryu M, Mulay SR, Miosge N, et al. Tumour necrosis factor-a drives Alport glomerulosclerosis in mice by promoting podocyte apoptosis. J Pathol 2011;226:120-31
   PubMed Web of Science ®Google Scholar
• Sedrakyan S, Da Sacco S, Milanesi A, et al. Injection of amniotic fluid stem cells delays progression of renal fibrosis. J Am Soc Nephrol 2012;23:661-73
   PubMed Web of Science ®Google Scholar
• Kaissling B, LeHir M, Kriz W. Renal epithelial injury and fibrosis. Biochim Biophys Acta 2013;1832:931-9
   PubMed Web of Science ®Google Scholar
• Ruggenenti P, Cravedi P, Remuzzi A. Mechanisms and treatment of CKD. J Am Soc Nephrol 2012;23:1917-28
   PubMed Web of Science ®Google Scholar
• Sugimoto H, Mundel TM, Sund M, et al. Bone-marrow-derived stem cells repair basement membrane collagen defects and reverse genetic kidney disease. Proc Natl Acad Sci USA 2006;103:7321-6
   PubMed Web of Science ®Google Scholar
• Prodromidi EI, Poulsom R, Jeffery R, et al. Bone marrow-derived cells contribute to podocyte regeneration and amelioration of renal disease in a mouse model of Alport syndrome. Stem Cells 2006;24:2448-55
   PubMed Web of Science ®Google Scholar
• Katayama K, Kawano M, Naito I, et al. Irradiation prolongs survival of Alport mice. J Am Soc Nephrol 2008;19:1692-700
   PubMed Web of Science ®Google Scholar
• Lebleu V, Sugimoto H, Mundel TM, et al. Stem cell therapies benefit Alport syndrome. J Am Soc Nephrol 2009;20(11):2359-70
   PubMed Web of Science ®Google Scholar
• Lees G, Helman RG, Kashtan CE, et al. A new form of X-linked dominant hereditary nephritis in dogs. Am J Vet Res 1999;60:373-83
   PubMed Web of Science ®Google Scholar
• Lees G, Helman RG, Kashtan CE, et al. A model of autosomal recessive Alport syndrome in English cocker spaniel dogs. Kidney Int 1998;54:706-19
   PubMed Web of Science ®Google Scholar
• Suleiman H, Zhang L, Roth R, et al. Nanoscale protein architecture of the kidney glomerular basement membrane. Elife 2013;2:e01149
   PubMed Web of Science ®Google Scholar
• Cosgrove D, Rodgers K, Meehan D, et al. Integrin alpha1beta1 and transforming growth factor-beta 1 play distinct roles in Alport glomerular pathogenesis and serve as dual targets for metabolic therapy. Am J Pathol 2000;157:1649-59
   PubMed Web of Science ®Google Scholar
• Kashtan CE, Kim Y, Lees GE, et al. Abnormal glomerular basement membrane laminins in murine, canine, and human Alport sydnrome: aberrant laminin alpha2 deposition is species independent. J Am Soc Nephrol 2001;12:252-60
   PubMed Web of Science ®Google Scholar
• Chen YM, Miner JH. Glomerular basement membrane and related glomerular disease. Transl Res 2012;160:291-7
   PubMed Web of Science ®Google Scholar
• Kreidberg JA, Donovan MJ, Goldstein SL, et al. Alpha 3 beta 1 integrin has a crucial role in kidney and lung organogenesis. Development 1996;122:3537-47
   PubMed Web of Science ®Google Scholar
• Nishiuchi R, Takagi J, Hayashi M, et al. Ligand-binding specificities of laminin-binding integrins: a comprehensive survey of laminin-integrin interactions using recombinant alpha3beta1, alpha6beta1, alpha7beta1 and alpha6beta4 integrins. Matrix Biol 2006;25:189-97
   PubMed Web of Science ®Google Scholar
• Sterk LM, Geuijen CA, van den Berg JG, et al. Association of the tetraspanin CD151 with the laminin-binding integrins alpha3beta1, alpha6beta1, alpha6beta4 and alpha7beta1 in cells in culture and in vivo. J Cell Sci 2002;115:1161-73
   PubMed Web of Science ®Google Scholar
• Baleato RM, Guthrie PL, Gubler M-C, et al. Deletion of CD151 results in a strain-dependent glomerular disease due to severe alterations of the glomerular basement membrane. Am J Pathol 2008;173:927-37
   PubMed Web of Science ®Google Scholar
• Sachs N, Kreft M, van den Bergh Weerman MA, et al. Kidney failure in mice lacking the tetraspanin CD151. J cell biol 2006;175:33-9
   PubMed Web of Science ®Google Scholar
• Meehan DT, Delimont D, Cheung L, et al. Biomechanical strain causes maladaptive gene regulation, contributing to Alport glomerular disease. Kidney Int 2009;76:968-76
   PubMed Web of Science ®Google Scholar
• Zallochi M, Johnson BM, Meehan DT, et al. Alpha 1beta1 integrin/rac1-dependent mesangial invasion of glomerular capillaries in Alport syndrome. Am J Pathol 2013;183:1269-80
   PubMed Web of Science ®Google Scholar
• Kashtan CE, Sibley RK, Michael AF, et al. Hereditary nephritis: Alport syndrome and thin glomerular basement membrane disease. In: Tisher CC, Brenner BM, editors. Renal pathology. 2nd edition. J. B. Lippincott, Philadelphia; 1994. p. 1239-67
   Google Scholar
• Rubel D, Frese J, Martin M, et al. Collagen receptors integrin alpha2beta1 and discoidin domain receptor 1 regulate maturation of the glomerular basement membrane and loss of integrin alpha2beta1 delays kidney fibrosis in COL4A3 knockout mice. Matrix Biol 2014;34:13-21
   PubMed Web of Science ®Google Scholar
• Heikkila P, Parpala T, Lukkarinen O, et al. Adenovirus-mediated gene transfer into kidney glomeruli using an ex vivo and in vivo kidney perfusion system – first step towards gene therapy of Alport syndrome. Gene Ther 1996;3:21-7
   PubMed Web of Science ®Google Scholar
• Finkel RS, Flanigan KM, Wong B, et al. Phase 2a study of ataluren-mediated dystrophin production in patients with nonsenses mutation Deschenne muscular dystrophy. PLoS One 2013;8:e81302
   PubMed Web of Science ®Google Scholar
• Mukherjee S, Thrasher AJ. Gene therapy for PIDs: progess, pitfalls and prospects. Gene 2013;525:174-81
   PubMed Web of Science ®Google Scholar
• Naldini L. Ex vivo gene transfer and correction for cell-based therapies. Nat Rev Genet 2011;12:301-15
   PubMed Web of Science ®Google Scholar
• Kashtan CE, McEnery PT, Tejani A, et al. Renal allograft survival according to primary diagnosis: a report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Nephrol 1995;9:679-84
   PubMed Web of Science ®Google Scholar
• Kashtan CE. Renal transplantation in patients with Alport syndrome. Pediatr Transplant 2006;10:651-7
   PubMed Web of Science ®Google Scholar
• Gross O, Borza DB, Anders HJ, et al. Stem cell therapy for Alport syndrome: the hope beyond the hype. Nephrol Dial Transplant 2009;24:731-4
   PubMed Web of Science ®Google Scholar
• Savige J. Alport syndrome: about time - treating children with Alport syndrome. Nat Rev Nephrol 2012;8(7):375-6
   PubMed Web of Science ®Google Scholar